11β-Hydroxysteroid dehydrogenase type 1 inhibitors with oleanan and ursan scaffolds

Molecular and Cellular Endocrinology

Volumn 301, Issue 1-2, 2009, Pages 132-136

  Blum, Andreas ^a   Favia, Angelo D ^b   Maser, Edmund ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

11 Hydroxysteroid dehydrogenase; Diabetes; Glucocorticoid metabolism; Metabolic syndrome; Obesity

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1 INHIBITOR; ENZYME INHIBITOR; LIGAND; TRITERPENOID; UNCLASSIFIED DRUG; 11BETA HYDROXYSTEROID DEHYDROGENASE 1; 11BETA HYDROXYSTEROID DEHYDROGENASE 2; CARBENOXOLONE; DRUG DERIVATIVE; HSD11B1 PROTEIN, HUMAN; HSD11B2 PROTEIN, HUMAN; OLEANANE; OLEANOLIC ACID; TRITERPENE; URSAN;

ADIPOCYTE; ARTICLE; DRUG INHIBITION; DRUG SCREENING; DRUG STRUCTURE; ENZYME SPECIFICITY; ENZYME SYNTHESIS; HUMAN; MUSCLE CELL; PRIORITY JOURNAL; CHEMISTRY; DRUG ANTAGONISM; ENZYME ACTIVE SITE; IC 50;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 2; CARBENOXOLONE; CATALYTIC DOMAIN; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; OLEANOLIC ACID; TRITERPENES;

EID: 60549109671     PISSN: 03037207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mce.2008.08.028     Document Type: Article

References (26)

1. Berman H.M., Westbrook J., Feng Z., Gilliland G., Bhat T.N., Weissig H., Shindyalov I.N., and Bourne P.E. The protein data bank. Nucl. Acids Res. 28 (2000) 235-242
2. Blum A., Martin H., and Maser E. Human 11beta-hydroxysteroid dehydrogenase 1/carbonyl reductase: recombinant expression in the yeast Pichia pastoris and Escherichia coli. Toxicology 144 (2000) 113-120
3. Bühler H., Perschel F.H., and Hierholzer K. Inhibition of rat renal 11β-hydroxysteroid dehydrogenase by steroidal compounds and triterpenoids; structure/function relationship. Biochim. Biophys. Acta 1075 (1991) 206-212
4. Glide 2007. Version 4.5, New York, NY: LLC.
5. Hughes K.A., Webster S.P., and Walker B.R. 11-Beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors in type 2 diabetes mellitus and obesity. Expert. Opin. Investig. Drugs 17 (2008) 481-496
6. Hult M., Shafqat N., Elleby B., Mitschke D., Svensson S., Forsgren M., Barf T., Vallgarda J., Abrahmsen L., and Oppermann U. Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons. Mol. Cell. Endocrinol. 248 (2006) 26-33
7. Kim D.H., Yu K.W., Bae E.A., Park H.J., and Choi J.W. Metabolism of kalopanaxsaponin B and H by human intestinal bacteria and antidiabetic activity of their metabolites. Biol. Pharm. Bull. 21 (1998) 360-365
8. Kotelevtsev Y., et al. 11β-Hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 14924-14929
9. Liu Y., Nakagawa Y., Wang Y., Li R., Li X., Ohzeki T., and Friedman T.C. Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice. Diabetes 52 (2003) 1409-1416
10. Livingstone D.E., Jones G.C., Smith K., Jamieson P.M., Andrew R., Kenyon C.J., and Walker B.R. Understanding the role of glucocorticoids in obesity: tissue-specific alterations of corticosterone metabolism in obese Zucker rats. Endocrinology 141 (2000) 560-563
11. Maestro 2007. Version 8, New York, NY: LLC.
12. Maser E., and Bannenberg G. The purification of 11β-hydroxysteroid dehydrogenase from mouse liver microsomes. J. Steroid Biochem. Molec. Biol. 48 (1994) 257-263
13. Maser E., Volker B., and Friebertshauser J. 11 Beta-hydroxysteroid dehydrogenase type 1 from human liver: dimerization and enzyme cooperativity support its postulated role as glucocorticoid reductase. Biochemistry 41 (2002) 2459-2465
14. Masuzaki H., Paterson J., Shinyama H., Morton N.M., Mullins J.J., Seckl J.R., and Flier J.S. A transgenic model of visceral obesity and the metabolic syndrome. Science 294 (2001) 2166-2170
15. Masuzaki H., et al. Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112 (2003) 83-90
16. Matsuda H., Li Y., Murakami T., Matsumura N., Yamahara J., and Yoshikawa M. Antidiabetic principles of natural medicines. III. Structure-related inhibitory activity and action mode of oleanolic acid glycosides on hypoglycemic activity. Chem. Pharm. Bull. (Tokyo) 46 (1998) 1399-1403
17. Miura T., Itoh Y., Kaneko T., Ueda N., Ishida T., Fukushima M., Matsuyama F., and Seino Y. Corosolic acid induces GLUT4 translocation in genetically type 2 diabetic mice. Biol. Pharm. Bull. 27 (2004) 1103-1105
18. Morton N.M., Holmes M.C., Fievet C., Staels B., Tailleux A., Mullins J.J., and Seckl J.R. Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice. J. Biol. Chem. 276 (2001) 41293-41300
19. Murakami T., Emoto A., Matsuda H., and Yoshikawa M. Medicinal foodstuffs. XXI. Structures of new cucurbitane-type triterpene glycosides, goyaglycosides-a, -b, -c, -d, -e, -f, -g, and -h, and new oleanane-type triterpene saponins, goyasaponins I, II, and III, from the fresh fruit of Japanese Momordica charantia L. Chem. Pharm. Bull. (Tokyo) 49 (2001) 54-63
20. Sandeep T.C., Yau J.L., MacLullich A.M., Noble J., Deary I.J., Walker B.R., and Seckl J.R. 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 6734-6739
21. Seckl J.R. 11beta-hydroxysteroid dehydrogenases: changing glucocorticoid action. Curr. Opin. Pharmacol. 4 (2004) 597-602
22. Shimizu K., Ozeki M., Tanaka K., Itoh K., Nakajyo S., Urakawa N., and Atsuchi M. Suppression of glucose absorption by extracts from the leaves of Gymnema inodorum. J. Vet. Med. Sci. 59 (1997) 753-757
23. Stewart P.M., Valentino R., Wallace A.M., Burt D., Shackleton C.H.L., and Edwards C.R.W. Mineralocorticoid activity of liquorice: 11 beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet ii (1987) 821-824
24. Walker B.R., Connacher A.A., Lindsay R.M., Webb D.J., and Edwards C.R. Carbenoxolone increases hepatic insulin sensitivity in man: a novel role for 11-oxosteroid reductase in enhancing glucocorticoid receptor activation. J. Clin. Endocrinol. Metab. 80 (1995) 3155-3159
25. Walker B.R., and Seckl J.R. 11beta-hydroxysteroid dehydrogenase type 1 as a novel therapeutic target in metabolic and neurodegenerative disease. Expert. Opin. Ther. Targets 7 (2003) 771-783
26. Yoshikawa M., Murakami T., and Matsuda H. Medicinal foodstuffs. X. Structures of new triterpene glycosides, gymnemosides-c, -d, -e, and -f, from the leaves of Gymnema sylvestre R. Br.: influence of gymnema glycosides on glucose uptake in rat small intestinal fragments. Chem. Pharm. Bull. (Tokyo) 45 (1997) 2034-2038